9 months (HT ≥ grade 2, n = 15) for those on BAY-BEV (Figure 1B). Development of HT was not related to survival following sorafenib without bevacizumab (BAY-NSCLC and BAY-CRC; P > 0.19), with a single exception where

patients on BAY-CRPC with < grade 2 HT (n = 37) actually had marginally non-significantly prolonged survival when compared to those individuals with HT ≥ grade 2 (n = 9; 1.8 versus 3.6 months respectively; P = 0.067). Figure 1 Kaplan-Meier curve of progression-free survival following treatment with bevacizumab in combination with docetaxel and thalidomide, n = 60 (A) , or bevacizumab in combination with sorafenib, n = 27 (B) , or sorafenib alone or in combination with bevacizumab, or cetuximab in patients with prostate cancer, various solid tumors, colon cancer, or NSCLC n = 113 (C) , or overall survival following treatment buy CP673451 with bevacizumab

in combination with sorafenib, n = 26 (D) versus development of ≥ Grade 2 toxicity – - or < Grade 2 toxicity ------ as indicated on each respective figure. Respective P = 0.0009, P = 0.052, P = 0.0003, and P = 0.0068 by a two-tailed log-rank test. As is indicated in Table 1, incidence of ≥ grade 2 HFSR was also associated with PFS in patients with colon cancer treated with sorafenib (P = 0.0065) with those patients having HFSR (n = 2) having a significantly longer response to sorafenib (8.7 months) than those without HFSR (4.7 months, SGC-CBP30 manufacturer n = 16). HFSR and PFS were either marginally not associated in patients on BAY-BEV (P = 0.094), or were

not associated on BAY-NSCLC and BAY-CRPC (P ≥ 0.29). However, since each group treated with sorafenib had a similar trend (i.e. patients with HFSR always had a longer median PFS) with a small number LY294002 of patients in each group (n ≤ 46), we pooled survival data obtained from the above trials to analyze the relationship between HFSR and PFS with greater statistical power. The pooled analysis significantly BIIB057 improved the relationship between PFS and HFSR with patients who developed HFSR following treatment with sorafenib, either as single agent or in combination with bevacizumab or cetuximab (n = 32), having a median PFS of 6.1 months compared with 3.6 months in patients without these toxicities (n = 81; P = 0.0003, Figure 1C). However, this pooled analysis should be interpreted with caution given that it is present only when heterogeneous groups of data obtained from patients are combined together. Association of these toxicities with OS was not significant with a single striking exception where those patients receiving the BAY-BEV combination had a significantly longer survival (P = 0.0093) if they developed hypertension during therapy (29 months, n = 14) when compared to those that did not develop hypertension (5.7 months, n = 12; Figure 1D). No other toxicity (i.e., rash/desquamation, diarrhea, or fatigue) was related to PFS (P > 0.05) for either drug.

No related posts.